Due to a complex interplay of genetic, lifestyle and environmental factors, as well as access to health care, the burden for advanced eye disease is highest among racial and ethnic minority groups.
But disparities in clinical trial participation persist, with an overrepresentation of white participants in most trials.
“In many of the pivotal trials for which our products have been approved, either industry sponsored or non-industry sponsored such as the DRCR Retina Network protocols, certain groups are underrepresented. And the challenge is that these are the same groups that